

Supplemental Table 1: Source of participants from InterLymph case-control studies

Study	Location	Year	Age (years)	Matching variables	Questionnaire	Sample type	NHL Patients	Controls		
							N (% IM history available)	N (% IM history available)	Source	Source type
BC	British Columbia, Canada	2000-2004	20-80	Age, sex, region	Self-administered and computer-assisted telephone interview	Blood or saliva	833 (93%)	848 (99%)	Random selection from client registry of Ministry of Health	population-based
Epilymph	Spain	1998-2003	17-96	Age, sex, region	Self-administered	Blood	441 (99%)	631 (99%)	Patients admitted to hospital for infectious, parasitic, mental, nervous, circulatory, digestive, endocrine, metabolic or respiratory conditions	clinic-based
	France	2000-2003	18-82	Age, sex, region	Self-administered	Blood	218 (100%)	276 (100%)	Patients admitted to hospital for infectious, parasitic, mental, nervous, circulatory, digestive, endocrine, metabolic and respiratory conditions	clinic-based
	Germany	1999-2002	18-82	Age, sex, region	Self-administered	Blood	518 (93%)	710 (95%)	Random selection from population registries	population-based
	Italy	1998-2004	25-81	Age, sex, region	Self-administered	Blood	222 (99.5%)	336 (100%)	Random selection from population registries	population-based
	Ireland	1998-2004	19-85	Age, sex, center	Self-administered	Blood	146 (97%)	208 (99.5%)	Patients admitted to hospital for infectious, parasitic, mental, nervous, circulatory, digestive, endocrine, metabolic or respiratory conditions	clinic-based
	Czech Republic	2001-2003	19-82	Age, sex, region	Self-administered	Blood	199 (99%)	304 (100%)	Patients admitted to hospital for infectious, parasitic, mental, nervous, circulatory, digestive, endocrine, metabolic and respiratory conditions	clinic-based
Mayo Clinic	Minnesota, USA	2002-2008	20-87	Age, sex, region	Self-administered	Blood	1128 (81%)	1319 (81%)	Patients attending a pre-scheduled general medical exam	clinic-based

NCI-SEER	Detroit; Iowa; Los Angeles; Seattle, USA	1998-2001	20-74	Age, region, race	Self-administered	Blood and Saliva	1321 (57%)	1057 (57%)	<65y: RDD; 65y+: random selection from CMS	population-based
SCALE	Denmark; Sweden	1999-2002	18-74	Age, sex, country	Telephone interview with a standardized, computer-aided questionnaire	Blood	3055 (99%)	3187 (99%)	Random selection from population registries	population-based
UCSF	San Francisco, CA, USA	1988-1995	21-74	Age, sex, region	In-person Interview	Blood	1302 (99.8%)	2402 (99.8%)	All ages: RDD; plus for 65y: random selection from CMS	population-based
Yale	Connecticut, USA	1995-2001	21-84	Age, sex	In-person Interview	Blood	600 (1%)	717 (100%)	<65y: RDD; 65y+: random selection from CMS	population-based

Supplemental Table 2: Associations between NHL and candidate risk variants [IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800896, rs1800890), TNFA (rs1800629), HLA I (rs6457327), and HLA II (rs10484561)]

	Genotyped Controls	Genotyped NHL Patients	OR ^a	95% CI	p-value
	N	N			
IL1A-889C>T (rs1800587)	2,317	2,084	1.00	[0.89, 1.13]	0.97
IL1B-511C>T (rs16944)	1,280	1,311	1.17	[1.00, 1.37]	0.05
IL1B-31C>T (rs1143627)	3,715	3,130	1.06	[0.96, 1.17]	0.22
IL1RN-9589A>T (rs454078)	2,319	2,068	1.19	[1.06, 1.35]	0.004 ^b
IL2-384T>G (rs2069762)	2,320	2,080	1.11	[0.99, 1.25]	0.09
IL6-174G>C (rs1800795)	2,347	2,099	0.93	[0.82, 1.05]	0.25
IL6-597G>A (rs1800797)	3,852	3,304	0.94	[0.85, 1.04]	0.22
IL10-1082A>G (rs1800896)	4,173	3,472	1.06	[0.96, 1.18]	0.24
IL10-3575T>A (rs1800890)	5,914	5,629	1.08	[1.00, 1.16]	0.06
TNF-308G>A (rs1800629)	5,562	5,546	1.12	[1.03, 1.22]	0.01
HLA: C>A (rs6457327)	2,963	2,457	0.82	[0.74, 0.92]	<0.001 ^b
HLA: T>G (rs10484561)	3,989	3,176	1.31	[1.17, 1.46]	<0.001 ^b

CI: confidence interval; NHL: non-Hodgkin lymphoma; OR: odds ratio

^a ORs, CIs, and p-values calculated using logistic regression models adjusted for age, sex, study center, and socioeconomic status

^b Evidence against the null hypotheses persists after accounting for multiple comparisons using pACT statistic.

Supplemental Table 3: Association between NHL and history of infectious mononucleosis by NHL subtype

	Control	NHL Patients			
	N	N	OR ^a	95% CI	p-value
All NHL	10,018	7,926	1.20	[1.04, 1.38]	0.01
CLL/SLL	10,018	1,466	1.51	[1.13, 2.02]	0.006 ^b
DLBCL	10,018	2,246	1.10	[0.89, 1.37]	0.37
FL	10,018	1,691	1.08	[0.86, 1.37]	0.49
MCL	10,018	325	2.29	[1.41, 3.75]	0.001 ^b
T-Cell	10,018	509	1.32	[0.89, 1.96]	0.17

CI: confidence interval; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; NHL: non-Hodgkin lymphoma; OR: odds ratio.

^a ORs, CIs, and p-values calculated using logistic regression models stratified by genotype and adjusted for age, sex, study center, and socioeconomic status.

^b Evidence against the null hypotheses persists after accounting for multiple comparisons using Bonferroni correction.

Supplemental Table 4: Association between IM history of infectious mononucleosis and T-cell lymphoma among genotyped participants stratified by *IL1B* (rs16944, rs1143627) and *IL6* (rs1800795, rs1800797) genotypes

Variant	Genotype	Controls		T-Cell Patients		OR ^a	95% CI	p-value
		IM-	IM+	IM-	IM+			
<i>IL1B</i> -511C>T (rs16944)	CC	559	35	42	5	1.91	[0.67, 5.45]	0.23
	TC/TT	654	32	47	3	1.39	[0.38, 5.11]	0.62
<i>IL1B</i> -31C>T (rs1143627)	TT	1626	86	95	7	1.55	[0.67, 3.62]	0.31
	CT/CC	1,907	96	100	4	0.92	[0.32, 2.63]	0.87
<i>IL6</i> -174G>C (rs1800795)	GG	734	54	46	5	1.25	[0.45, 3.50]	0.67
	CG/CC	1,461	98	74	4	0.78	[0.27, 2.26]	0.64
<i>IL6</i> -597G>A (rs1800797)	GG	1298	66	73	6	1.30	[0.51, 3.27]	0.58
	AG/AA	2,364	124	135	5	0.77	[0.30, 1.98]	0.59

CI: confidence interval; IM: infectious mononucleosis; OR: odds ratio.

^a ORs, CIs, and p-values calculated using logistic regression models stratified by genotype and adjusted for age, sex, study center, and socioeconomic status. Effect estimates are unstable due to low sample sizes in IM+ T-cell patients' strata.